Most MS patients are older at diagnosis, often delay starting treatment, and are likely to remain with the first-choice treatment, according to a survey conducted on MSology, the sister site of NeuroSens. Read More
Latest News
Progressive MS studies
May 19, 2017REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 AAN 2017: There is a growing body of data on the use of disease-modifying therapies in patients with progressive multiple sclerosis. The following is a summary of key studies presented at AAN 2017. Read More
Disease-modifying therapies in MS: long-term data
May 10, 2017REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 – The following summarizes data from key studies presented at the American Academy of Neurology annual meeting on the long-term use of disease-modifying therapies in multiple sclerosis. Read More
AAN 2017 DAILY REPORT
April 27, 2017Report from the American Academy of Neurology annual meeting, Boston MA, 22-28 April 2017
Thursday Edition
Wednesday Edition
Tuesday Edition Read More